CROI 2015 Program and Abstracts

Keyword Index

Incidence; 157, 254, 612, 709, 831, 841, 1026 Incidence assay; 624, 626 Incidence rates; 638 Incident tuberculosis; 938 India; 641, 1016 Indoleamine 2,3-dioxygenase (IDO); 295, 317 Indoleamine 2,3-dioxygenase-1; 899

Intracellular pharmacology; 81, 83, 526 Intrinsic immunity; 194, 386 iPrEx; 977 IRES translation; 412 IRF3; 187 Iron; 461, 567 Isoniazid preventative therapy; 1108 ITPA; 518 IV drug users; 654 – J – Jaundice; 515 – K – K65R; 596, 597 Kaplan-Meier; 156 Kaposi sarcoma; 87, 88, 721, 722, 723 Kaposi sarcoma–associated herpesvirus; 87 Kenya; 102, 597, 624, 712, 853 Key populations; 102 Key populations (MSM); 102, 1063, 1063 Kidney; 742 Kidney function; 792, 797 Kidney transplantation; 798, 799 Killer-cell immunoglobulin-like receptor (KIR); 275, 276, 924 Late presentation; 911 Late-stage disease; 221 Latency; 371, 387, 394, 403, 412, 413, 416, 418, 423, 428LB • Models; 390, 424 • Reversing agents; 372, 406, 428LB Latent; 827LB • HIV; 376 • HIV-1 reactivation; 391, 397, 417, 419, 421LB • HIV-1 reservoir; 395, 396 • Reservoir; 392, 397, 427 • Tuberculosis; 817, 885 Latin America; 580 LDV/SOF; 82 Lean mass; 140 Lectin binding; 215 LEDGF; 540 Ledipasvir; 152LB, 689, 692 Lentivirus; 207 Lesotho; 1034, 1103 Leukocyte-endothelial cell interactions; 735 Levonorgestrel; 85LB, 858 LGMD1F; 196 Life expectancy; 161, 1052 LILRA3; 282 Limiting antigen avidity enzyme immunoassay; 625 Linear mixed models; 576 Linkage; 1078 Linkage to care; 29, 99, 100, 154, 632LB, 661, 666, 1005, 1016, 1069, 1074, 1090, 1093, 1097, 1111 Killing; 167 KIR2D; 275 KIR3DL1/S1; 277 KLF2/Statin; 298LB KSHV; 69 Kynurenine-to-tryptophan (KT) ratio; 295 – L – L-selectin; 426 Laboratory reporting time; 613 Lamivudine; 542, 566 Late HIV diagnosis; 999, 1001

Linkage to HIV care; 93 Lipid profile; 930 Lipids; 309, 782, 787 Lipoatrophy; 804 Lipodystrophy; 140, 779, 803 Lipohypertrophy; 804 Liver; 679, 808 • Biopsies; 706 • Cirrhosis; 645 • Disease; 677, 805 • Disease progression; 657, 680 • Fibrosis; 660, 806, 807 • Progression; 636 • Transplantation; 640, 799 Liver-related death; 637 Liver-related endpoint; 671 Local and systemic PK; 524 Long-term nonprogressor; 347 Long-term; 156, 882 Long-term follow-up; 36, 405

Inducible HIV-1; 398 Infant; 33, 897, 948 Infant HIV-free survival; 871 InfantTB; 872 Infants; 879, 880, 883, 905 Infection; 600 Infection risk; 862 Infections; 941 Infectivity; 39, 209 Inflammasome; 313, 323

Inflammation; 47, 134, 266, 270, 309, 313, 314, 315, 319, 454, 496, 500, 501, 565, 730, 737, 745, 761, 763, 778, 803, 934, 1050, 1085

Inflammation markers; 738, 772, 797 Inflammatory biomarkers; 312, 756, 810 Inflammatory markers; 305, 491 Infliximab; 813 Influenza vaccination; 947 Influenza vaccine; 342 Ingenol; 416 Inhibitor; 212, 539

Longitudinal; 927, 1068 Longitudinal study; 437 Lopinavir; 588, 960

Lopinavir/ritonavir; 36, 374, 511, 527, 955 Loss to follow-up; 156, 558, 1009, 1077 Low-income countries; 71, 1118 Low-level viremia; 107 LRA; 416 LTBI; 827LB Lung cancer; 727, 728 Lung function; 490 Lymph node; 188, 188 Lymphocyte activation; 320, 772 Lymphogranuloma venereum; 845 Lymphoid tissue; 325 Lymphoma; 70, 429, 719 Lysosomal integrity; 395 – M – M2-like macrophages; 677 mAb; 371 mAb combination; 346 Macaque; 363, 433, 476, 510, 966LB

Inhibitory receptor; 389LB Injectable contraception; 28 Injection drug use; 14, 217, 598 Injury; 1055 iNKT cells; 705 Innate immunity; 41, 52, 79, 123, 124, 184, 191, 192, 279, 281, 289, 307, 547, 811 Innate response; 43, 286 Innate-likeT cell; 278 Innovative trial designs; 95LB, 131 Inpatient; 1100 Insulin; 880 Insulin resistance; 744, 745, 771, 787, 929 Insurance; 1064, 1066, 1070 Integrase; 540, 591 Integrase Inhibitor (INI); 140, 594, 608, 9851 Integrase mutation; 121 Integrase strand transfer inhibitor; 591, 609, 953 Integrated DNA; 354 Integrated prevention services; 128, 135 Integration; 611 Integration site analysis; 199, 381 Integration sites; 21, 105, 107 Intelligence quotient; 495 Intensification; 549 Interaction; 521 Interferon; 40, 44, 184, 280, 671, 681 • Alfa; 414 • Alpha; 54LB, 186, 217 • Gamma; 281, 313 • Responses; 498 Interleukin 6; 1049 Interleukin-21; 358 Interleukin-7; 334 International physical activity questionnaire (IPAQ); 489 Internet; 1025 Intimate partner violence; 853, 980 Intravaginal ring; 1107 • Stimulate genes; 292 Interferon-free; 649, 691

Macaque models; 286 Macrocyclization; 693 Macrophage; 183, 188, 199, 204, 205, 268, 361, 410, 418, 476, 501, 502, 528, 529, 753, 835 • Activation; 676 • Polarization; 61 • Tropism; 440 Magnetic resonance imaging; 935 Magnetic resonance spectroscopy; 441 Maintenance therapy; 551, 554LB MAIT cell; 278 Malaria; 513, 883 Malawi; 1046 Male circumcision; 30, 1084, 1085, 1086, 1087, 1089 Male partners; 1018 Malnutrition; 876, 915 Mangabeys; 279 Mannose binding lectin; 481 MAP2; 464 Maraviroc; 86LB, 959, 208, 263, 441, 547, 549, 564, 633, 769LB, 814, 950, 959, 960, 964, 965, 993 Marginal structural modeling; 578 Marginalized populations; 245 Marijuana; 1006 Markov model; 97

Keyword Index

687

CROI 2015